The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria

Exclusion Criteria

• •1. Women who are pregnant or cannot eliminate the possibility to be pregnant.
• •2. Estimated creatinine clearance \<30 ml/min/1.73 m2 using Cockcroft equation.
• •3. LVEF(Left ventricular ejection fraction) \< 35% by the most recent imaging test within 7 days prior to procedure.
• •4. Unstable ventricular arrhythmias.
• •5. High bleeding risk, active peptic ulcers or cerebrovascular accident or transient ischemic attack within the past 6 months.
• •6. Known contraindication to anticoagulants and antiplatelets therapy.
• •7. Known hypersensitivity to aspirin, clopidogrel, heparin, iodinated contrast, ticagrelor, bivalirudin, metal materials in stent.
• •8. Any intervention for not target vessel within 48 hours after the study procedure.
• •9. Any conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation.
• •1. The reference diameter of target vessel is less than 2.5 mm.
• •2. The target lesion involves myocardial bridge.
• •3. The target lesion is in the left main coronary artery or the damage is observed in the ostium.
• •4. Severe calcification in the target vessel.
• •5. Severe tortuosity in the target vessel.
• •6. Multiple contiguous stent implantation in the target vessel.
• •7. Subject has coronary artery spasm.
• •8. In-stent restenosis.
• •9. Any study lesion characteristic that, in the investigator's opinion, is not available for intravascular imaging.